RENBP and atherosclerosis: The treatment of DPVD using SMTAD predominantly targets pathways related to cancer, lipid and atherosclerosis, the AGE-RAGE signaling pathway, the interleukin IL-17 signaling pathway, the tumor necrosis factor signaling pathway (TNF), the endocrine resistance pathway, the cellular senescence pathway, and 178 other pathways, as illustrated in Figure 6.